Nubeqa Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Darolutamide

Indications/Uses

Adult men w/ nonmetastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease; metastatic hormone-sensitive prostate cancer (mHSPC) in combination w/ docetaxel.

Dosage/Direction for Use

Adult nmCRPC & mHSPC 600 mg bd. mHSPC In combination w/ docetaxel: Administer 1st 6 cycles of docetaxel w/in 6 wk after start of darolutamide. Patient experiencing ≥grade 3 toxicity or intolerable AR W/hold or reduce dose to 300 mg bd until symptoms improve. Moderate hepatic & severe renal impairment (eGFR 15-29 mL/min/1.73 m²) not receiving haemodialysis Starting dose: 300 mg bd.

Administration

Should be taken with food: Swallow whole.

Contraindications

Hypersensitivity. Women who are or may become pregnant.

MIMS Class

Cancer Hormone Therapy

ATC Classification

L02BB06 - darolutamide ; Belongs to the class of anti-androgens. Used in treatment of neoplastic diseases.

Regulatory Classification

POM

Presentation/Packing

Form

Nubeqa FC tab 300 mg

Packing/Price

1's

Nubeqa

darolutamide

Manufacturer:

Orion